Hepatitis C virus infection and chronic renal disease: A review

被引：15
作者：
Goel A. [1 ]
Bhadauria D.S. [2 ]
Aggarwal R. [1 ]
机构：
[1] Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow
[2] Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow
来源：
Indian Journal of Gastroenterology | 2018年 / 37卷 / 6期
关键词：
Diagnosis; End-stage renal disease; Hemodialysis; Hepatitis C virus; Kidney; Prevalence; Prevention; Transmission; Treatment; Viral hepatitis;
D O I：
10.1007/s12664-018-0920-3
中图分类号：
学科分类号：
摘要：
Hepatitis C virus (HCV) is a parenterally-transmitted hepatotropic virus that often causes chronic infection, which can progress to cirrhosis and hepatocellular carcinoma. Development of highly effective direct-acting anti-viral agents (DAAs) has led to a paradigm change in the treatment of HCV infection over the last 4–5 years. Patients with chronic kidney disease (CKD) are at a higher risk of acquiring HCV infection. In these patients, diagnosis of HCV infection, assessment of the consequent liver disease and management of HCV infection pose some specific problems. This article reviews the available recent information on HCV infection and CKD, including the association between these conditions and their effect on each other, and prevention, evaluation, and management of HCV infection in persons with CKD. This review looks at this issue particularly from the perspective of readers in Asia, especially India, since the epidemiology of HCV-CKD association and the repertoire of anti-HCV drugs available in this region differ from those elsewhere. © 2018, Indian Society of Gastroenterology.
引用
收藏
页码：492 / 503
页数：11
相关论文
共 92 条
[1]  
Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M., Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome, Science, 244, pp. 359-362, (1989)
[2]  
Kamal S.M., Acute hepatitis C: a systematic review, Am J Gastroenterol, 103, pp. 1283-1297, (2008)
[3]  
KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease, Kidney Int Suppl, 8, pp. 91-165, (2018)
[4]  
Levey A.S., Coresh J., Greene T., Et al., Chronic kidney disease epidemiology collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate, Ann Intern Med, 145, pp. 247-254, (2006)
[5]  
Welzel T.M., Petersen J., Herzer K., Et al., Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort, Gut, 65, pp. 1861-1870, (2016)
[6]  
Goel A., Bhargava R., Rai P., Aggarwal R., Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: an Indian experience, Indian J Gastroenterol, 36, pp. 227-234, (2017)
[7]  
Goel A., Bhadauria D.S., Kaul A., Et al., Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients, Indian J Gastroenterol, 36, pp. 137-140, (2017)
[8]  
Taneja S., Duseja A., De A., Et al., Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients, Nephrology (Carlton), 23, pp. 876-882, (2018)
[9]  
Global health sector strategy on viral hepatitis, (2016)
[10]  
Fabrizi F., Marcelli D., Bacchini G., Guarnori I., Erba G., Locatelli F., Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease, Nephrol Dial Transplant, 9, pp. 780-784, (1994)
12345678910